ANDA 203339, held by Lupin. Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 203339 (Amabelz), held by Lupin, was first approved by FDA on Jun 20, 2016, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 20, 2016 | Original application | Approved | None posted |
| Amabelz0.5MG;0.1MG · tablet;oral | Estradiol; Norethindrone Acetate | Rx |
| Amabelz1MG;0.5MG · tablet;oral | Estradiol; Norethindrone Acetate | Rx |
| Nov 9, 2026 | Supplement 18Manufacturing | Approved | None posted |
| Sep 17, 2026 | Supplement 15Labeling · Standard review | Approved | None posted |
| Mar 15, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 21, 2017 | Supplement 1Manufacturing | Approved | None posted |
| Jun 20, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters